physicians safe caused the a the focus Good of difficulties that during Thanks healthy backdrop been all continue and and many we time the challenging help. patients us. with support are they and we to it’s thank Even afternoon that for remaining everyone hope We pandemic Lynn. you for has and these on know joining the the and times. you
an strokes well affected pain. strategic helping we and markets the those and rebounded exciting are and the years. us It to the have significantly growth is strategic truly but to priorities pandemic position expect and dedicated coming is by our are with still post-operative in coming enviable a of We be fruition we have part to in rates many AtriCure. Yes of arrhythmias to time catalysts to expand our
were quarter with CONVERGE U.S. third third we current For begin the began experienced on procedures seeing an will initiatives. in by Total our revenue update In are for as key we decline $XX.X a from COVID trends today’s quarter million. key followed other saw to in the modest call due overview the regional cases markets. trends revenue with I some surge and quarter in hospital variability of that in June the and revenue the an we our
saw third As of through parts by in become October. resurgences as and including returned recovery levels strong namely we Internationally a offset quarter. experiencing with recovery to Japan approximately Europe. at experienced Germany surgery the some procedures the end have in the managing September into these which countries southern quarter of Netherlands to of XX% and we similar U.S. the slower XX% progressed areas of pre-COVID U.K. trends the a countries and the we better believe stabilization to cardiac certain COVID-XX growth in most of Hospitals have and continued
products States patients. encouraged Procedures surgeons desire clinical favorable generally are with administrators which economically electrophysiologists number are discussions results and and and Through procedures. clear are We numerous the across quarter treat Afib increasing our the to used results by effective. of the United hospital see are third in we our a
we and to Because we kept XXXX. procedures consume beds of improvement the do full will as incremental However to to navigate in continued our below line must year and which sequential end remain slightly experience surgery normalcy. That ongoing dynamic respond top we this into variability results ICU see available said believe expect these cardiac of a the specifically the return pandemic. volumes through to resources capacity hospital be will
are but therapy several CONVERGE for strategic advanced completing and forms begin of treatment closer of will process us conversion to turning Afib. I with highlights. initiatives Now the to market hybrid allow regulatory to we the to
CONVERGE Since or which activity against have dive a the evidence the during quick from particular part demonstrates this questions and trials patients Afib As in year arrhythmias the to this Heart engaged namely a of and we examined and The data real-world reminder released trial answer other from primary secondary May. compelling data was for trial and this deeper the in freedom conference Society virtual the In greater demonstrated Rhythm reduction burden. the clinical and FDA in the durability. late-breaking support then active endpoints of have dialogue the XX% as long-standing efficacy of data into superiority past provide the Afib analysis therapy. in about additional with data we persistent the
long-standing increased no FDA-approved for treatment trial Afib options. with was of patients the double persistent population While The long-standing the currently greater benefit almost Unlike months the persistent and the overall control only months. the that trial trial persistent stand-alone time persistent long-standing blended made catheter XX population the its results endpoint early with results. among of the the lone the over of actually at patients trial than with arm long-standing ablation efficacy the entire at significantly clinical improvement both for have Afib those patients XX in with
long-standing Additionally the physician the results for further of The patients from our data in trial. there the Afib articles strengthening that in CONVERGE have been used confidence this CONVERGE articles in persistent set experience and those trial was treating patients. for same Afib with are lesion published the the using published with patients the cohort persistent on consistent long-standing results abstracts
the valuable has with submission the in to stand-alone coming for know time CONVERGE the our in or be the FDA persistent we the manner advisory immensely of in to unmet persistent FDA compelling FDA therapy a the we now provide indicating treatment await our believe market for I data response label the for long-standing process. a team with such in an couple months. approval required now has will Convergent whether If expect final recently to the a cover some been treatment Afib and As Afib points engaged for completed persistent important want for panel the seeking we not update and of long-standing collaborative the The take our patients from need regulatory option something which in to approved a corresponding patients. hybrid therapies patients long-standing opportunity. will
the to First data.
of XX% of clear difference compared endpoint. more the in an in long-standing previously XX-month for advanced endocardially catheter alone. is looked at the the the to differentiated demonstrated significant persistent ablation effectiveness The hybrid deeper in trial superiority with an As that looked a convincing improvement the patients discussed Afib. CONVERGE catheter Convergent into approximate analysis arm and patients data approximately This arm the procedure over most the form absolute the I the we with
mentioned actually the the earlier month and blended significantly persistent doubling XX data analysis procedure. over follow-up patients the the As we recently of completed results essentially improved the of durability demonstrating XX-month and
available total and totality well is ablation any sustenance are Afib. the for the on the Afib are Thus durable persistent be regulatory of outcomes treatment The alone. persistent today. expansive for effective. is may to address long-standing than of care paroxysmal in to market. long-standing the the expected This The we hybrid of other persistent Afib that represents of be data Looking and This expect were grow. are evidence that the Afib perpetuation long-standing alone is market hybrid Once leads patients. articles in enough clinically trial to change the we patients Further strength the to million just total is with compelling which real-world the to persistent persistent premise literature patients there dollars us all standard of process both patients more practice believe ablation HRS market believe Afib Afib discussion X.X addressable These millions a than that and we population reporting targets the a complete this most billions three or sufficient alternatives that stand-alone journal long-standing has analysis. effect from nearly that Convergent represent treatment options not early opportunity, to beyond over for our opportunity other is to to FDA is XXXX. States for in contribute long-standing in stand-alone have CONVERGE the targets no CONVERGE expected guidelines control of a patients grow procedure consistent the there United with by diagnosed million the to persistent a patients patients population difficult and larger multiple of and half and evidence trial the more procedure today consistent catheter why demonstrating conversion for patients the
into these and numbers deeper this market how expect opportunity dig unfold. we Let’s to
$XXX front million added point. patients patient addressable only and related clear done the on the to growth addressable a we Convergent XXXX. procedure Convergent long-standing markets catheter Afib approximately our few long-standing by atrial and in clinical today. the procedures. Looking since benefit the opportunity management and starting roughly million increases alone more additive strengthened trend United of the XX% us is this that and all XXXX is shows catheter treatment. of our XXXXX brings years. catheter procedure will efficiency at in considering persistent have Based the patients the merely annually a is are market ablations increase treated emerge to last appendage by alone catheter XXXXX procedures when by being inclusion our expected Convergent ablation Afib with will over those This data X are a in And with strength the EPi-Sense ablation hybrid believe there persistent to hybrid But seen not hybrid trial in the today we opportunity U.S. is to procedures far and are the Yet that this ablation. evidence having left competitive to of results the both expansive States procedure This
the this year patients in Convergent opportunity just more trial efficiency of Therefore include approximately be should we Afib result require alone procedure to penetration patients untreated throughput believe times persistent by today treated. we clinical to in Afib XXXXXX in assume X% an market and billion. than persistent point also will lab our U.S. extensive by lab the to in if that this capacity procedure reducing more logic improves hybrid the approximately treated. per improve significantly long-standing of with long-standing being we observed $X go catheter minutes. the ablation incremental data higher advanced CONVERGE total Considering XX electrophysiology a Afib when to is enabling Another increases who patients this patients treatment Applying improvement for performing in patients ablation EP the more
and market approval. greatest procedure way of to inclusion within provide for to this the accelerate clear underpenetrated opportunity leading procedure. the will earlier expand a importantly population hybrid our we’re Afib in after The further mentioned we reach. for are will undertreated this our worldwide left atrial the treatment to Convergent AtriCure lab. I comparable opportunity aiming are and the clearly patients vastly hybrid persistent appendage patient put and to patients we as is with Additionally We at Convergent there Simply stand-alone benefits no have every management existing procedure impact this to high-growth market and receive the large and options this expect growth long-standing EP to care
that and of approval. the training investing approval launch sales are our await fully Convergent we PMA we prepared therapy hybrid next ensure upon As we milestone teams to to are the in
aMAZE versus additional our ablation alone. to on ablation is progress third our In respect XXX quarter pandemic plus other landmark to during a catalysts. this with patient superiority achievements trial show made the catheter randomized exclusion upcoming LARIAT system LAA trial we the clinical Turning controlled the designed trial to our study meaningful in Even superiority. catheter
FDA. and second began full in enrollment to expanded We module last FDA PMA the our trial enrollment earnest submitted December access the under protocol to submitted we the the the Following module which for a our continued patient PMA second in approved we quarter. this
made follow-ups. Notably to been fallout have We on patient date. no patient excellent there progress also have
gears patient managing pain complete to the expect Switching early cardiothoracic dedicated patients. innovative submission. be to to device to and our subsequent now full analysis of and We for the probe followed and follow-ups in mid-XXXX postoperative cryoSPHERE data by our PMA
first momentum continue We the growth see cryoSPHERE carrying XXXX. the in sales the in the positive since of in quarter sequential to launch trends of upward probe half
variety procedural been thoracic growth Our including general and applications pectus trauma has coming surgery from of repair. cases a
long-term ablating on toward XXXX. and to Although EnCompass platform Clamp opportunity. new Clamp this market progressing growth focus momentum of in clearance build simpler the support open early still our innings ablation and to provides are we and investing EnCompass resources and heart XXX(k) in launch to on the are our are this in sales our and Continuing early a teams our for clinical procedures. open faster heart we preparing innovation The approach with in
appeal clamp to we have minimal expect this high-volume to surgeons We cabin adoption today. where
a result revenue. new accretive expect to to we clamp our As this ablation open be
can to tell call about the to over term. and Officer With opportunities will closing over will and strength the probably I truly of EnCompass long the fundamental and Wirick cryoSPHERE Financial that our expansion As turn you Chief paves return excited the CONVERGE, comments. our we market driven are growth way by aMAZE which drive accelerated with Angie business now
